AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma

NORTH CHICAGO, Ill. and NEWARK, Calif.: NORTH CHICAGO, Ill. and NEWARK, Calif., June 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Teneobio, Inc. announced today that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed...

Click to view original post